|

ARX788 Clinical Trials

2 actively recruiting trials across 2 locations

▲ +1 trial since June 2026

Also known as: Anti-Her2 ADC, Anti-Her2 Mab PAF- MMAF Toxin Oxime Conjugate ARX-788, Antibody-drug Conjugate ARX788, Anvatabart Opadotin

Pipeline

Phase 2: 2

Top Sponsors

  • QuantumLeap Healthcare Collaborative1
  • Laura Huppert, MD, BA1

Indications

  • Breast Cancer2
  • Cancer2
  • Hormone Receptor Negative Tumor1
  • Hormone Receptor Positive Tumor1
  • HER2 Low Breast Carcinoma1

Birmingham, Alabama1 trial

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

University of Alabama at Birmingham

Phase 2

San Francisco, California1 trial

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

University of California, San Francisco

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.